Sarepta Therapeutics annual operating margin
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sarepta Therapeutics's operating margin was −37.54% for fiscal 2025.
View full Sarepta Therapeutics company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −37.54% | −49.73 pp |
| 2024 | 2024-12-31 | 12.20% | +35.59 pp |
| 2023 | 2023-12-31 | −23.39% | +40.16 pp |
| 2022 | 2022-12-31 | −63.55% | +11.52 pp |
| 2021 | 2021-12-31 | −75.07% | +48.69 pp |
| 2020 | 2020-12-31 | −123.76% | +61.51 pp |
| 2019 | 2019-12-31 | −185.27% | −71.12 pp |
| 2018 | 2018-12-31 | −114.15% | −3.12 pp |
| 2017 | 2017-12-31 | −111.03% | +4809.28 pp |
| 2016 | 2016-12-31 | −4,920.31% | +12652.24 pp |
| 2015 | 2015-12-31 | −17,572.55% | −16201.34 pp |
| 2014 | 2014-12-31 | −1,371.21% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 4.04% | −18.48 pp |
| Q1 2026 | 2026-03-31 | 108.45% | +157.57 pp |
| Q4 2025 | 2025-12-31 | −111.36% | −136.69 pp |
| Q3 2025 | 2025-09-30 | −27.94% | −33.10 pp |
| Q2 2025 | 2025-06-30 | 22.52% | +22.72 pp |
| Q1 2025 | 2025-03-31 | −49.12% | −58.83 pp |
| Q4 2024 | 2024-12-31 | 25.34% | +18.59 pp |
| Q3 2024 | 2024-09-30 | 5.16% | +11.90 pp |
| Q2 2024 | 2024-06-30 | −0.19% | +55.67 pp |
| Q1 2024 | 2024-03-31 | 9.71% | +69.36 pp |
| Q4 2023 | 2023-12-31 | 6.75% | +52.03 pp |
| Q3 2023 | 2023-09-30 | −6.74% | +56.48 pp |
| Q2 2023 | 2023-06-30 | −55.87% | +44.08 pp |
| Q1 2023 | 2023-03-31 | −59.65% | −13.64 pp |
| Q4 2022 | 2022-12-31 | −45.28% | +13.92 pp |
| Q3 2022 | 2022-09-30 | −63.22% | −42.58 pp |
| Q2 2022 | 2022-06-30 | −99.95% | +18.19 pp |
| Q1 2022 | 2022-03-31 | −46.01% | +75.55 pp |
| Q4 2021 | 2021-12-31 | −59.20% | +79.99 pp |
| Q3 2021 | 2021-09-30 | −20.64% | +92.23 pp |
| Q2 2021 | 2021-06-30 | −118.14% | +6.11 pp |
| Q1 2021 | 2021-03-31 | −121.56% | −4.06 pp |
| Q4 2020 | 2020-12-31 | −139.20% | +90.76 pp |
| Q3 2020 | 2020-09-30 | −112.88% | +11.91 pp |
| Q2 2020 | 2020-06-30 | −124.26% | +166.62 pp |
| Q1 2020 | 2020-03-31 | −117.50% | −29.71 pp |
| Q4 2019 | 2019-12-31 | −229.96% | −64.87 pp |
| Q3 2019 | 2019-09-30 | −124.79% | −35.47 pp |
| Q2 2019 | 2019-06-30 | −290.88% | −150.22 pp |
| Q1 2019 | 2019-03-31 | −87.79% | −40.21 pp |
| Q4 2018 | 2018-12-31 | −165.09% | −124.68 pp |
| Q3 2018 | 2018-09-30 | −89.31% | +10.58 pp |
| Q2 2018 | 2018-06-30 | −140.66% | +40.25 pp |
| Q1 2018 | 2018-03-31 | −47.58% | +192.57 pp |
| Q4 2017 | 2017-12-31 | −40.41% | — |
| Q3 2017 | 2017-09-30 | −99.90% | — |
| Q2 2017 | 2017-06-30 | −180.91% | — |
| Q1 2017 | 2017-03-31 | −240.15% | — |
Over the last five reported fiscal years, Sarepta Therapeutics's operating margin increased from −123.76% to −37.54%, a change of +86.22 percentage points. The latest reported quarter, Q2 2026, shows 4.04%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sarepta Therapeutics filings at SEC.gov ↗